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A B S T R A C T
The complexity of the human brain emerges from a long and ﬁnely tuned developmental process orchestrated by
the crosstalk between genome and environment. Vis à vis other species, the human brain displays unique
functional and morphological features that result from this extensive developmental process that is, un-
surprisingly, highly vulnerable to both genetically and environmentally induced alterations. One of the most
striking outcomes of the recent surge of sequencing-based studies on neurodevelopmental disorders (NDDs) is
the emergence of chromatin regulation as one of the two domains most aﬀected by causative mutations or Copy
Number Variations besides synaptic function, whose involvement had been largely predicted for obvious rea-
sons. These observations place chromatin dysfunction at the top of the molecular pathways hierarchy that ushers
in a sizeable proportion of NDDs and that manifest themselves through synaptic dysfunction and recurrent
systemic clinical manifestation. Here we undertake a conceptual investigation of chromatin dysfunction in NDDs
with the aim of systematizing the available evidence in a new framework: ﬁrst, we tease out the developmental
vulnerabilities in human corticogenesis as a structuring entry point into the causation of NDDs; second, we
provide a much needed clariﬁcation of the multiple meanings and explanatory frameworks revolving around
"epigenetics", highlighting those that are most relevant for the analysis of these disorders; ﬁnally we go in-depth
into paradigmatic examples of NDD-causing chromatin dysregulation, with a special focus on human experi-
mental models and datasets.
1. Introduction
Neurodevelopmental Disorders (NDDs) constitute a broad spectrum
of diseases originated during the development of the central nervous
system (CNS). They are characterized by an early childhood onset
leading to varying degrees of neuropsychiatric impairment, often in
combination with a plethora of accompanying manifestations, whose
speciﬁc conﬁgurations represent both a diagnostic and therapeutic
challenge.
In this review we focus on NDD caused by genetic alterations of
high, usually complete penetrance and characterized by often over-
lapping phenotypes. Importantly, the causative mutations target several
convergent molecular axes, with genes either belonging to the same
class (e.g. lysine demethylases) or operating in the same molecular
pathway (e.g. Polycomb-mediated chromatin regulation). The genetic
causes of a major NDD class, such as the Autism Spectrum Disorders
(ASD), provide an examplary case. The Simons Foundation Austim
Research Initiative (SFARI) currently lists 910 genes whose mutations
lead to syndromic and non-syndromic ASDs. Following a Gene
Ontology (GO) analysis of these genes (Fig. 1), a strong statistical en-
richment emerges for many categories related for neuronal activity and
function as well as for gene expression control. Indeed, 87 out of 910
genes are involved in molecular functions such as “demethylase ac-
tivity”, “transcription coactivator activity”, “transcription factor ac-
tivity”, “direct ligand regulated sequence-speciﬁc DNA binding”, and
“chromatin binding”, which highlights the pivotal role of the gene ex-
pression regulation in mediating common Gene Regulatory Networks
(GRNs) in vulnerable cell types, thus constituting the basis of wide-
spread genetic dysregulation and its overlapping phenotypical mani-
festations.
As the distinctively human features aﬀected in NDDs, in terms of
cognition and behaviour, are arguably linked to the mechanisms en-
gaged in cortical expansion (Rakic, 2009), we ﬁrst focus on the speciﬁc
susceptibilities of human cortex development. Next, we mobilize the
most rigorous and productive notions of epigenetics and clarify their
importance for NDD, considering the relevance of gene expression
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control in their pathogenesis. On the basis of this framework, we then
undertake an exhaustive review of the mechanisms of gene expression
regulation whose derangements have been causally linked to NDDs.
Speciﬁcally, to help the reader appreciate how the interplay of epige-
netic mechanisms underlies the molecular-phenotypical convergence,
we review the molecular functions and physiological roles of histone
methylation, acetylation, phosphorylation, DNA methylation, and nu-
cleosome remodeling, and we underscore the importance of the dy-
namic balance of each of these mechanisms in the NDDs associated to
them.
1.1. Vulnerable stages of human neural development
The human cortex depends on two waves of cell proliferation. First,
symmetrical divisions at the ventricular and subventricular areas, 10
times more prolonged in humans than in rodents, are responsible for
the expansion of the progenitor pool, resulting in the enlarged sub-
ventricular zone (SVZ) in the cortex and subgranular zone (SGZ) in the
hippocampus. Later, a stage of asymmetric neurogenic divisions, 20
times longer in humans, determines the number of neurons in the dif-
ferent cortical layers (Florio and Huttner, 2014). Human cortical neu-
rogenesis occurs predominantly during gestation from week 5-6 post-
conception, but may continue up to 2.5 years of age (Florio and
Huttner, 2014). The prolonged unfolding of neurogenic potential, along
Fig. 1. Gene Ontology analysis of SFARI genes responsible
for ASDs. The GO was performed using the WEB-based
GEne SeT AnaLysis Toolkit (http://www.webgestalt.org/)
with an Overrepresentation Enrichment Analysis. Gene
ontology was used as a functional database. The gene list
contains 910 user IDs in which 902 user IDs are un-
ambiguously mapped to the unique Entrez Gene IDs and 8
user IDs are mapped to multiple Entrez Gene IDs or could
not be mapped to any Entrez Gene ID. The GO Slim sum-
mary are based upon the 902 unique Entrez Gene IDs.
Among the 902 unique Entrez Gene IDs, 694 IDs are an-
notated to the selected functional categories and also in the
reference gene list, which are used for the enrichment
analysis. The analysis was performed with the following
parameters: Minimum number of Entrez Gene IDs in the
category:1; Maximum number of Entrez Gene IDs in the
category:2000; FDR Method:BH; Signiﬁcance Level:
FDR < 0.05.
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with the highly vascularized nature of the developing SVZ and SGZ,
have both been invoked as reasons for the vulnerability of the devel-
oping human brain (Baburamani et al., 2012). These proliferative
stages are particularly prone to the accumulation of genetic lesions
associated with DNA replication and repair, including Single Nucleotide
Variations (SNVs) and insertions-deletions (indels) (Ernst, 2016). Also,
due to the prolonged nature of corticogenesis, the precise stage at
which environmental or genetic insults hit has a discernible impact. In
broad terms, the stage of impact inﬂuences the phenotypic outcomes in
two possible ways: defects occurring during the early phase produce a
cortex with a small surface area but normal or enlarged thickness (lis-
sencephaly); conversely, defects during the phase of formation of ra-
dially aligned columns of cortical progenitors, (i.e., ontogenetic col-
umns) produces polymicrogyria with thinner cortex and relatively
normal or larger surface (Geschwind and Rakic, 2013). This stage-
speciﬁcity may be due to the timing of expression of the aﬀected gene,
or the time at which the buﬀering eﬀects of compensatory circuits
ceases.
After the progenitor pool is established, diﬀerentiating neurons ra-
pidly multiply their synaptic connections. In humans, synapse produc-
tion begins at around 20 weeks of gestation and increases quickly after
birth, peaking at 2 years of age. By this stage, the number of synapses is
approximately 50% higher than that seen in adults, followed by a
process of synaptic pruning that continues well into adolescence
(Petanjek et al., 2011). Environmental and genetic factors aﬀecting
these processes contribute to functional abnormalities, such as in-
creased ﬁlopodia-to-spine ratios and abnormal protrusion densities, a
common feature in many NDDs during early childhood (Govek et al.,
2005).
The vast majority of neuropsychiatric disorders and intellectual
disabilities are linked to improper synaptic pruning (Paus et al., 2010)
underlying the biomedical and behavioral implications of the synaptic
establishment phase. Moreover, a prolonged synaptic pruning and re-
modeling are characteristic of areas heavily involved in complex cog-
nitive tasks such as the human prefrontal cortex (Paspalas et al., 2009),
increasing the chance that the impact of even minuscule early impair-
ments of the mechanisms regulating synaptic connectivity gets magni-
ﬁed upon development.
1.2. Genetic susceptibilities
Despite the considerable variation in brain sizes across healthy in-
dividuals, ranging up to 1.7 fold in the same gender, as well as mi-
crostructural variation often found in the neocortex (Toro et al., 2008),
the general anatomical distribution and connectivity between regions is
highly conserved, suggesting that a substantial proportion of the ge-
netic underpinnings for this architecture is conserved across the human
population. Furthermore, when considering only protein coding se-
quences, the diﬀerences between human and chimpanzee genomes is
about 1% (Varki and Altheide, 2005). Although there is a signiﬁcant
amount of neutral and non-coding variation, it is estimated that the
total SNVs, indels, and structural chromosomal changes make up about
4% of this divergence, with only a few of them resulting in functional
alterations to proteins (Sudmant et al., 2013). This evidence suggests
that diﬀerences in coding sequences alone may not account for the
substantial phenotypic and functional complexity observed in humans,
instead diﬀerences in the rate at which genetic variants are ﬁxed in the
human population, copy number polymorphisms as well as epigenetic
regulation all contribute to a phenotypic “plasticity” and species-spe-
ciﬁc diﬀerences between humans and great apes (Varki et al., 2008).
This accumulation of genetic variation has been associated to a pro-
nounced incidence of genomic disorders aﬀecting brain development.
In general, the increased presence in humans and other great ape
lineages of complex loci, such as those in which germline structural
mutations in many diﬀerent ancestors have given rise to complex pat-
terns of variation, has created species-speciﬁc hotspots prone to copy
number variation (Boettger et al., 2012). The accumulation of these
hotspots during evolution has contributed to the emergence of human-
speciﬁc disorders of genetic origin including dyslexia, intellectual dis-
ability (ID), attention-deﬁcit hyperactivity disorder (ADHD), Autism
spectrum disorders, and schizophrenia, as well as neurodegenerative
conditions such as Alzheimer's disease (Geschwind and Rakic, 2013).
In addition to germline genetic variation, the combination of pro-
longed proliferation of neural progenitors and the extended lifespan of
mature neurons make the human brain particularly prone to somatic
mosaicism, leading both to higher neuronal diversity (with its possible
functional correlates) but also to increasing likelihood of disease (Wei
et al., 2016; Weissman and Gage, 2016). In fact, within the same in-
dividual, neuronal populations may harbor structural variants in the
range of several megabases, including copy number variants (CNVs),
inversions, translocations and even whole-chromosome gains or losses
(McConnell et al., 2013). Genome-wide analyses performed in brains
from autistic individuals revealed the existence of convergent mole-
cular abnormalities in ASD, among which several high conﬁdence genes
provide a molecular neuropathological basis for the disease (Voineagu
et al., 2011). Recent evidence indicates that postzygotic mosaic muta-
tions may underlie a signiﬁcant proportion of ASD cases, adding further
complexity in terms of the stage-speciﬁc impact of mutational burden.
Recent eﬀorts, such as the Brain Somatic Mosaicism Network (BSMN),
aim at eliminating the bias of typical genome-wide association studies
and exome sequencing, which rely on assuming a ﬁxed nature of the
genome throughout time, while simultaneously trying to weigh the
contribution of cumulative variation across development (McConnell
et al., 2017). Preliminary ﬁndings of the BSMN have identiﬁed a list of
well-deﬁned mosaicisms, which cause a broad spectrum of disorders
(Freed et al., 2014; McConnell et al., 2017). Altogether, somatic mo-
saicism may signiﬁcantly contribute to the enormous range of pheno-
typical manifestations observed in NDDs.
1.3. Epigenetic susceptibilities
Recently, chromatin regulation has been recognized as one of the
two domains most aﬀected by genetic lesions causative of neurodeve-
lopmental disorders (De Rubeis et al., 2014; Lasalle, 2013; Pinto et al.,
2014; Ronan et al., 2013a). This allows to reframe the impact of epi-
genetic dysregulation on human neural development along with a ﬁrst
structuring classiﬁcation: i) neurodevelopmental disorders caused by
mutations in chromatin regulators (in which epigenetic disruption is
originally encoded in a genetic lesion); and ii) neurodevelopmental
disorders caused by environmentally-induced epigenetic dysfunction.
The two possibilities are not mutually exclusive, as genetically encoded
epigenetic vulnerabilities may enhance sensitivity to environmental
disruptors and, viceversa, the environmentally-induced epigenetic dis-
ruption may alter DNA management processes and usher into genetic
lesions.
Regardless of which of the two scenarios is prevalent (or exclusive)
for a given neurodevelopmental condition, both beneﬁt from a clar-
iﬁcation of what epigenetics refers to and of which aspect of its mul-
tifaceted meanings is most relevant for investigating neurodevelop-
mental disorders. We thus refer the reader to recent theoretical
systematizations of the concept of epigenetics, including a historical
reconstruction of their changes in meaning, which can be brieﬂy sum-
marized as follows (Boniolo and Testa, 2012; Meloni and Testa, 2014).
In Waddington's original deﬁnition, the epigenotype referred to the
intermediate phenomena linking genotype to phenotype, a notion that
was couched from the outset in developmental terms, with the gra-
phical rendering of the epigenetic landscape in which diﬀerentiation
was plotted over a map of progressively restricted and irreversible cell
fates induced by developmental cues. This integration of the classical
view of embryological epigenesis with genetics paved the way to
modern epigenetics (Waddington, 1942). However, over the years, the
term has adopted several meanings and nuances, among which three
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are the most relevant for our analysis. The ﬁrst is what we refer to as the
'strong' meaning of epigenetics, deﬁning those phenomena that are in-
herited across generations of cells (or organisms) independent of un-
derlying changes in DNA sequence. The second is an extension of the
ﬁrst, which makes it relevant also for non-dividing cells or for organ-
isms that do not reproduce and considers as epigenetic those pheno-
types that are stably maintained across the lifespan of cells or organisms
long after their initial trigger has waned (Beck et al., 2010). Finally, the
third is the currently most prevalent but also the shallowest meaning of
the word, anchored to a literal reading of the etymology of the term,
from the greek επί, epì = “above” and γεννετικός, gennetikòs = “ge-
netics”. In this nearly all-encompassing sense, epigenetics is widely and
increasingly used as synonymous of gene regulation and de facto
equated with chromatin, a discursive move that has proceeded to engulf
all of the transcription regulation (and possibly beyond) independent of
whether its features show any stability or inheritance (Ptashne, 2007).
Indeed, at least four main domains of chromatin regulation (DNA
methylation, histone post-translational modiﬁcations, chromatin re-
modelling and nucleosome positioning) are usually welcomed under
the rubric of epigenetics, though only for few of them exists bona ﬁde
evidence or even just a plausible hypothesis or indeed a rationale for
stability and/or inheritance. A case in point is the notion of the histone
code itself, which was initially proposed to endow the repertoire of
histone post-translational modiﬁcations (HPTMs) with the same degree
of functional cogency borrowed from the genetic code (Allis and
Jenuwein, 2016). The realization of the striking diversity of patterns of
co-occurring modiﬁcations (Wang et al., 2008) made it however in-
creasingly problematic to pursue the code-based simpliﬁcation of such a
rich array of chromatin functions, ushering into more nuanced but still
to be settled explanatory frameworks for the palimpsest of HPTMs,
especially given the rapidly evolving knowledge on the degree of their
inheritability (Heard and Martienssen, 2014; Probst et al., 2009). While
a full account of the debate on what counts as epigenetic is beyond the
scope of this work, we consider it essential to clarify the multiplicity of
its meanings for a heuristically productive investigation of NDD. Spe-
ciﬁcally, we argue that for NDDs pathogenesis the most relevant deﬁ-
nitions are the ﬁrst and the second, given the vulnerability and sensi-
tivity of CNS development. Indeed, given the extensive phases of cell
proliferation that uniquely characterize human CNS, whether dysre-
gulation in the genome-wide occupancy of a given chromatin mark can
be transmitted across development is key, especially depending on what
stage the dysregulation becomes manifest. Similarly, also the other
strict criterion for adjudicating the epigenetic nature of biological
phenomena, namely whether a given phenotype, for example chro-
matin conﬁguration or transcriptional state, is stably maintained in
non-dividing cells even long after the initial trigger has removed, is also
paramount, given the protracted, oftentimes life-long survival of neu-
rons generated during embryonic life.
Finally, one last word of critical scrutiny concerns the widespread if
inadvertent conﬂation of the role of histone modiﬁcations with that of
the enzymes that catalyse them. Given the number of histone gene
clusters in mammals (Banaszynski et al., 2010), strict functional ex-
periments that probe the eﬀect of a speciﬁc modiﬁcation by disabling
the histone aminoacid targeted by the modiﬁcation are still unfeasible.
The function of a given modiﬁcation is usually inferred by the pheno-
type observed upon mutation of the eﬀector enzyme. While this as-
sumption is clearly warranted in many cases, it implies that the impact
of mutations in a histone modiﬁer is primarily if not exclusively linked
to its downstream consequences on histones. Several lines of evidence
point however to a more complex situation. For instance, an elegant
study that used Crispr/Cas9 to uncouple the enzymatic from non-en-
zymatic functions of KMT2C and D found that both enzymes promoted
enhancer RNA (eRNA) synthesis and promoter transcription largely
independent of their contribution to H3K4 monomethylation (Dorighi
et al., 2017; Rickels et al., 2017), inviting caution in the acritical at-
tribution of neurodevelopmental phenotypes to the histonic
consequences of mutations in chromatin regulators. Similarly, mice
homozygous for a KMT2A allele lacking the catalytic domain are viable
and recapitulate only a minor fraction of the major developmental
phenotypes (including embryonic lethality per se) observed upon full
gene ablation (Terranova et al., 2006).
For these reasons in this review, whenever possible, we highlight
the cases in which the ﬁrst and the second deﬁnition of epigenetics
apply. However, given the widespread use of the third meaning, whose
rubric encompasses many causative genes of NDD, we also discuss its
relevance in depth, especially given the fact that chromatin as a whole
is a critical domain of dysregulation enriched in ASD and ID causative
genes.
2. Histone post-translational modiﬁcations
2.1. H3K4 methylation
The overall relevance of lysine 4 of histone H3 methylation
(H3K4me) for physiological human brain development is underscored
by its signiﬁcant genome-wide redistribution in neurons from the pre-
frontal cortex during the ﬁrst year of life (Cheung et al., 2010) as well
as by its remarkable locus-speciﬁc redistribution in prefrontal cortex
neurons of individuals aﬀected by ASD (Shulha et al., 2012). Several
lines of evidence spanning multiple models support the heritability of
H3K4 methylation: i) H3K4me is required for the inheritance of the rate
of transcription across cell division in Dictyostelium (Muramoto et al.,
2010); ii) enzymatic complexes of the Trithorax and Polycomb group
families remain associated to DNA and re-impose the H3K4me (along
with the antagonistic H3K27me) modiﬁcation patterns that had been
erased through DNA replication in Drosophila (Petruk et al., 2012); iii)
also in human cells, KMT2A engages in mitotic bookmarking, re-
maining stably associated to promoters within condensed mitotic
chromatin whereby it accelerates their transcriptional reactivation
following mitotic exit (Blobel et al., 2009); iv) ﬁnally, genetic evidence
has shown that mutations in the Trithorax family prevent the main-
tenance of patterns of gene activation, indicating their key role in
sustaining expression programs during lineage speciﬁcation (Kennison,
1995). Thus, mutations of the enzymes controlling the H3K4 methyla-
tion are candidates to have a transgenerational impact, thereby al-
lowing to consider H3K4me as a bona ﬁde epigenetic mark, borrowing
from the ‘strong’ deﬁnition of epigenetics outlined in the introduction.
In mammals, H3K4 can be mono-, di- or tri-methylated and is as-
sociated to diﬀerent genomic regulatory elements. The deposition of
these marks has been linked to the activity of the following ten enzymes
displaying diﬀerent speciﬁcities, both regarding the level of methyla-
tion and the genome-wide distribution of the modiﬁcation: KMT2A/B/
C/D/F/G, ASH1L, SMYD3, SETD7, and PRMD9. In mammals, the KMT2
family of methyl-transferases is composed by 6 members (KMT2A-G,
excluding the catalytically inactive KMT2E), which arose from dupli-
cation events during evolution and constitute the catalytic cores of the
COMPASS (COMplex of Proteins ASsociated with Set1) complexes
(Schuettengruber et al., 2011). These complexes are mainly responsible
for H3K4 methylation at promoters and enhancers (Allis et al., 2007). In
metazoans, the COMPASS complexes can be grouped in three pairs of
paralogs based on their methylase catalytic core: the KMT2A/B,
KMT2C/D and KMT2F/G. COMPASS complexes share in fact a set of
core subunits (ASH2L, RBBP5, WDR5 and DPY30) while each also
contains a set of speciﬁc ones (Dou et al., 2006; Wysocka et al., 2005).
Moreover, COMPASS complexes contain one of the two lysine de-
methylases KDM6A and KDM6B (also known as UTX and JMJD3, re-
spectively) (Hong et al., 2007; Xiang et al., 2007) which act as coun-
terpart for the post-translational modiﬁcations performed by the
Polycomb Repressive Complex 2 (PRC2), H3K27me3 (Czermin et al.,
2002).
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2.1.1. KMT2A and KMT2B
In vitro, recombinant KMT2A and KMT2B are proﬁcient at mono-
and di-methylating H3K4, whereas they display low trimethylation
activity. It has been shown, however, that the substrate speciﬁcity and
activity of holocomplexes can diﬀer signiﬁcantly from that of bacte-
rially expressed subunits, indicating that in vivo the presence of cofac-
tors and/or post-translational modiﬁcations of the KTM2 enzymes is
likely critical to determine their enzymatic output. This is shown in the
paradigmatic example of the oocyte, in which KMT2B is solely re-
sponsible for the deposition of bulk H3K4me3 (Andreu-Vieyra et al.,
2010). The assessment of H3K4me status upon selective and/or com-
binatorial KMT2s inactivation is thus a more cogent measure of their
cell type-speciﬁc function.
Mutations in KMT2A and KMT2B cause two sharply distinct disease
phenotypes, pointing to an only partial degree of redundancy between
these two paralogs, a feature that is supported by several lines of evi-
dence: ﬁrst, mutations in either of the two genes resulted in embryonic
lethality with non-overlapping developmental phenotypes (Glaser
et al., 2006; Yu et al., 1995); however, KMT2B displayed a surprisingly
speciﬁc and narrow window of requirement for normal development
(Glaser et al., 2009). Second, in embryonic stem cells, KMT2B is se-
lectively required for performing H3K4me3 at bivalent promoters,
while KMT2A is redundant (Denissov et al., 2014; Hu et al., 2013).
Third, conditional ablation of Kmt2a in the murine adult subventricular
zone revealed its essential role in neurogenesis (Lim et al., 2009).
However, the key neurogenic genes that fail to be expressed upon loss
of Kmt2a, such as Dlx2, retained normal H3K4me3 but also H3K27me3.
Therefore the key function of the KMT2 COMPASS complex, in this
instance, is not per se the trimethylation of lysine 4 (compensated
presumably by KMT2B), but the resolution of the bivalent status in-
stantiated by the demethylation of H3K27me3 (Park et al., 2014).
Fourth, depletion of Kmt2a from either mouse postnatal forebrain or
the adult prefrontal cortex (PFC) resulted in increased anxiety and
impaired working memory, due to failure to sustain the immediate
early wave of gene expression required for synaptic plasticity
(Jakovcevski et al., 2015). Of note, while the loss of Kmt2b in the same
CamkII-expression domain also resulted in learning phenotypes
(Kerimoglu et al., 2013), its selective ablation from the adult PFC
caused only minor cognitive impairment. Instead, loss of Kmt2b in the
hippocampus impaired memory function, suggesting a brain area-spe-
ciﬁc action for these enzymes.
In human, mutations in KMT2A, previously known as MLL1, cause
Wiedemann-Steiner syndrome (WSS), characterized by individuals with
facial dysmorphysms, intellectual disability, hypotonia, ASD, and de-
velopmental delay (Jones et al., 2012; Sun et al., 2017). In an inter-
esting example of phenotypic and genotypic convergence, WSS cases
have also been reported harbouring mutations in KMT2A and subunits
or regulators of the cohesin complex SMC1A and SMC3, which are re-
sponsible for a subset of cases of Cornelia De Lange Syndrome (CdLS), a
multisystemic NDD deﬁned by intellectual disability, facial dys-
morphism, pre- and post-natal delay, microcephaly, heart defects,
upper limb abnormalities, and genitourinary anomalies (Yuan et al.,
2015). Specularly, KMT2A was found mutated in an individual diag-
nosed with CdLS. Wiedemann-Steiner syndrome is usually caused by
nonsense and frame-shift mutations; nevertheless, some missense mu-
tations were also reported both in the CXXC domain and in the PHD
ﬁnger domain, the latter being a mediator of protein-protein interac-
tions. Subjects aﬀected by missense mutations have a more severe
clinical phenotype, featuring seizures, microcephaly, and im-
munodeﬁciency featuring low levels of immunoglobulins. Taken to-
gether, these ﬁndings suggest that haploinsuﬃciency of the catalytic
activity is not the only mechanism through which a mutation in KMT2A
can cause a developmental phenotype, as missense mutations in other
domains might also impair speciﬁc GRNs involved in hematopoiesis and
the immune system (Stellacci et al., 2016).
Although KMT2A and KMT2B perform the same histone
modiﬁcation, they have diﬀerent physiological roles. This is reﬂected
by the fact that mutations in KMT2B also cause an early-onset dystonia,
accompanied by microcephaly, and mild-to-moderate ID in two thirds
of the aﬀected individuals; brain anomalies such as symmetrical hy-
pointensity in the globus pallidi were reported as well (Meyer et al.,
2016; Zech et al., 2016).
It is now evident that mutations in KMT2A or KMT2B yield clearly
diﬀerent phenotypes, pointing to the notion that H3K4me3 dysregula-
tion is not per se pathological; it is rather the lack of either protein that
aﬀects the deposition of the mark at enzyme-speciﬁc genomic regions,
thus aﬀecting diﬀerent, speciﬁc GRNs.
2.1.2. KMT2C and KMT2D
KMT2C and KMT2D perform H3K4 monomethylation (H3K4me1), a
hallmark of enhancer regions (Kaikkonen et al., 2013; Lee et al., 2013),
through their SET domain. The COMPASS complex containing KMT2C
and D also includes KDM6A (already known as UTX), whose de-
methylase activity counteracts the PRC2 axis and renders the H3K27
substrate available for p300/CBP-mediated acetylation (Wang et al.,
2016). Consequently, the combined action of the mono-methylation
deposition and UTX activity was shown to control cell fate transitions of
macrophages and ESCs through enhancer activation (Kaikkonen et al.,
2013; Wang et al., 2016)
KMT2C and KMT2D also have partially redundant roles. The dele-
tion of either gene aﬀects global H3K4me1 deposition only marginally.
The resulting phenotypes in mouse models are remarkably diﬀerent:
Kmt2c depleted mice die after birth without morphological alterations,
whereas Kmt2d KO mice die during embryonic development, at em-
bryonic stage E9.5, due to defects in heart development, adipogenesis,
and myogenesis. In addition, the conditional depletion of Kmt2d in
somatic precursors showed decreased brown adipose tissues formation
and muscle mass levels, causing the death of pups by breathing dys-
function (Lee et al., 2013), thus indicating a tissue-speciﬁc action for
each enzyme.
The eﬀects of KMT2C and D on gene transcription are not solely
caused by their catalytic activity: it was recently shown that the ab-
sence of both KMT2D and C has an impact on Pol II occupancy at en-
hancers and on enhancer RNA (eRNA) transcription, resulting in the
downregulation of target genes. On the contrary, the presence of two
catalytically inactive genes leads to the loss of H3K4me1 and reduction
of H3K27Ac with minor eﬀects on eRNA and target genes transcription.
Therefore, KMT2C-D mediate long-range interactions between en-
hancer and target genes independently of their catalytical activity
(Dorighi et al., 2017; Rickels et al., 2017).
Mutations in KMT2D cause 60-70% of Kabuki syndrome (KS),
whereas 10% of KS are linked to mutations in KDM6A. KS is a rare
multisystemic NDD ﬁrst described in 1981 (Kuroki et al., 1981; Niikawa
et al., 1981) and it is mainly characterized by stereotypical facies, mild
to moderate ID, congenital heart defects, microcephaly, immunological
disorders and endocrinological alterations (Lederer et al., 2012; Ng
et al., 2010). The remaining 20% of cases are caused by mutations in
unidentiﬁed genes (Miyake et al., 2013). Given the involvement of
KMT2D and KDM6A in the deposition of enhancer-deﬁning marks, KS
was deﬁned as enhanceropathy (Smith and Shilatifard, 2014). Studies
in a catalytically inactive Kmt2d+/βGeo mouse model demonstrated
genome-wide deﬁciency of H3K4me3, impaired adult neurogenesis in
the dentate gyrus (DG), and hippocampal memory defects, all of which
were rescued by the inhibition of histone deacetylases (Bjornsson et al.,
2014). More recently, quantitative imaging of adult neurogenesis in
Kmt2d+/βGeo mouse models revealed alterations in neural stem cells
(NSCs) and neural progenitor cells (NPCs). Single-cell expression pro-
ﬁling of adult NPCs revealed divergent maturation trajectories that
mirror the bifurcation of proliferation pathways, suggesting that the
pathophysiological basis of ID in KS involves aberrations in NSC cell
cycle, as well as proliferation, maturation, and integration defects of
NPCs in the adult hippocampus (Benjamin et al., 2017). However,
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according to the last discoveries made by Dorighi and Rickles, since
these studies employed a mouse model which does not mimic the
haploinsuﬃciency, it is possible that it might not completely re-
capitulate KS pathogenesis, as the complete removal of the entire gene
product leads to a more severe phenotype when compared to the in-
active enzyme (Dorighi et al., 2017; Rickels et al., 2017). Knockdown
experiments in D. rerio underlined the involvement of KDM6A and
KMT2D in the development of brain and heart and recapitulated the
cranio-facial anomalies typical of KS (Van Laarhoven et al., 2015). Al-
though KMT2C and D have a partially redundant eﬀect (Lee et al.,
2013), only KMT2D-dependent eﬀects are responsible for KS, as KMT2C
has never been found mutated in this syndrome. Instead, KMT2C was
found mutated in 4 out of 9 patients with Kleesftra Syndrome (see
below), who lacked an EHMT1 mutation (Kleefstra et al., 2012). Ad-
ditionally, copy number variants of KMT2C were associated with ASD
risk (Sanders et al., 2015). The ﬁrst enzyme discovered to be able to
demethylate lysine residues was KDM1A (aka LSD1), which can remove
H3K4me1 and H3K4me2 but does not demethylate H3K9, H3K27, and
H4K20 (Shi et al., 2004). Notably, KDM1A mutations have been linked
to a clinical phenotype related to the KS and KBG syndromes, usually
caused by ANKRD11 mutations (Chong et al., 2016; Tunovic et al.,
2014), as well as to severe non-syndromic intellectual disability (Rauch
et al., 2012). In addition, KDM5B, which removes H3K4me1, me2, and
me3, has not been found mutated itself but represses FOXG1 and
HOXA5. Respectively, FOXG1 was found to be causative of the Rett
syndrome, while HOXA5 is a deregulated gene both in Kabuki and
CHARGE (see below) syndromes (Tan et al., 2003; Yamane et al.,
2007).
2.1.3. KMT2F and KMT2G
Recombinant KMT2F (known as SETD1A) and G deposit all three
combinations of H3K4me in vitro, but in vivo they are responsible for the
bulk deposition of H3K4me3, which is found at transcription start sites
(TSSs) (Deng et al., 2013; Shilatifard, 2006). Both KMT2F and G have
an essential role in the early embryonic development and KMT2F de-
pletion is embryonic lethal (Bi et al., 2011; Bledau et al., 2014; Tusi
et al., 2015).
KMT2F mutations are associated with schizophrenia (Takata et al.,
2014, 2016). Regarding KMT2G, it is included with 30 other genes in a
region on 12q24.31, whose microdeletion causes a syndromic NDD
characterized by ID, developmental delay, seizures and dysmorphic
features. By focusing only on deleted regions shared among individuals,
the range of responsible genes was restricted to ﬁve genes, among
which KMT2G was suggested as a key actor (Palumbo et al., 2015).
Moreover, a noncoding regulatory region of HCFC1, which is a med-
iator of both KMT2F/KMT2G and KMT2A (Wysocka et al., 2003;
Yokoyama et al., 2004), is mutated in in individuals with a Non-syn-
dromic ID (Huang et al., 2012).
2.2. H3K9, H3K36, and H4K20 modiﬁcations
Other less well-studied histone methylation residues are H3K9,
H3K36, and H4K20. Their degree of inheritability is still undetermined.
Although it has been shown that H3K9me is quickly restored after
mitotic division (Steﬀen and Ringrose, 2014) virtually nothing is known
about the inheritability of H3K36 and H4K20. In C. elegans, it was found
that MES-4 is responsible for H3K36me3 deposition (Rechtsteiner et al.,
2010). Moreover, it was shown that H4K20me is not properly inherited
while it is restored during the cell cycle (Pesavento et al., 2008; Scharf
et al., 2009). H3K36me3 is deposited throughout the gene body of
active genes to prevent spurious transcription initiation. H3K36me3
recruits both the RPD3S complex, which catalyses deacetylation of
transcribed regions, and DNMT3B, which catalyses DNA methylation
(Carrozza et al., 2005; Li et al., 2007; Neri et al., 2017). H3K9 me-
thylation displays a wide range of functions in the genome. H3K9me1 is
found at the TSS of transcribed genes (Barski et al., 2007), H3K9me2 is
associated with X-inactivation and transcriptional repression
(Rougeulle et al., 2004; Wang et al., 2008), whereas H3K9me3 is as-
sociated with gene silencing and heterochromatin through the recruit-
ment of DNMT3B and HP1 (Lehnertz et al., 2003). Likewise, H4K20
methylation is associated to diﬀerent chromatin statuses. H3K20me1
and H4K20me2 are found on active genes, and they are relevant for the
cell cycle, though they have diﬀerent distribution (Beck et al., 2012;
Kuo et al., 2012; Wang et al., 2008). In contrast, H4K20me3 is asso-
ciated to gene and transposone silencing (Schotta et al., 2004; Wang
et al., 2008). Mutations in the genes capable of performing these three
HPTMs are causative of NDD.
EHMT1 catalyses mono- and di-methylation of H3K9 and it is able
to recruit PRC2 (Mozzetta et al., 2014); additionally, it is capable of
activating gene expression via an enzyme-independent mechanism
(Koemans et al., 2017). In humans, it is mainly expressed in the fetal
and adult brain, kidney, spleen, and thymus (Kurotaki et al., 2001).
Mutations on EHMT1 cause Kleefstra syndrome (KLS), which is
deﬁned by severe ID, distinctive facies, hypotonia, microcephaly, sei-
zures and heart defects (Iwakoshi et al., 2004; Kleefstra et al., 2006).
KLS has also been linked to mutations in SMARCB1, MBD5, NR1I3, and
KMT2C (Kleefstra et al., 2012) thus constituting another example of
phenotypic convergence. Such a convergence is conserved across evo-
lution, as the D. melanogaster paralogs of EHMT1 and KMT2C/D, G9a
and Trr, have common direct targets (Koemans et al., 2017). Never-
theless, observations regarding the function in CNS development of
Ehmt1 in rodents are nuanced: Ehmt1+/− mice displayed cognitive
deﬁcits such as learning and memory issues, and, at the synaptic level,
the dendritic arborisation and the number of mature spines were re-
duced in hippocampal CA1 pyramidal neurons (Balemans et al., 2013).
However, more recently, learning and memory tasks assessed in the
same Ehmt1+/− mice in a low-stress and unaversive environment
showed unhindered general learning deﬁcits. The authors suggested
that the previous result could be due to enhanced anxiety in Ehmt1+/−
mice and only to a lesser extent to impaired cognitive ability. Fur-
thermore, an increase in proliferation in the subgranular zone of the
dentate gyrus (assessed by BrdU incorporation) and a simultaneous
improvement in spatial learning (assessed by location discrimination
tasks) were observed in this model (Benevento et al., 2017), thus
making the link between EHMT1 and cognitive defects less obvious in
mice.
EHMT1-deposited methylation is counteracted by the PHF8 de-
methylase, which removes the H3K9-me1, me2, and H4K20me1 marks.
PHF8 is known to be important for brain and craniofacial development
in D. rerio (Qi et al., 2010), and it is altered in an X-linked mental re-
tardation syndrome associated with cleft lip and palate (Laumonnier
et al., 2005; Siderius et al., 1999).
The family of NSD enzymes (coded by NSD1, NSD2, and NSD3) is
responsible for a variety of H3 and H4 modiﬁcations, and their muta-
tions cause Sotos syndrome and Beckwith Wiedemann syndrome
(NSD1), Wolf-Hirschhom syndrome (NSD2) and hereditary acute mye-
loid leukemia (NSD3).
In the presence of nucleosomal H3, NSD1 performs H3K36 and
H4K20 methylation (Li et al., 2009). Moreover, disruption of the SETD2
enzyme, which deposits H3K36me3 (Sun et al., 2005), causes Luscan-
Lumish syndrome (LLS) and a Sotos-like syndrome. LLS is also an
overgrowth syndrome, featuring ID, ASD, developmental delay and
seizures (Lumish et al., 2015; Luscan et al., 2014). Despite the in-
volvement in the deposition of the same histone modiﬁcations, loss of
function murine models for Nsd1 and Nsd2 exhibit diﬀerent pheno-
types. Nsd1 depleted mice do not complete gastrulation (Rayasam et al.,
2003), while Nsd2 knockout mice display anomalies typical of WHS but
die after 10 days (Nimura et al., 2009).
Sotos syndrome and Beckwith-Wiedemann syndrome (BWS), caused
by mutations in NSD1, both feature overgrowth. Sotos syndrome is
characterized by rapid growth, ID, macrocephaly, cerebral, gigantism
and increased risk of tumor formation (Le Marec et al., 1999;
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Maldonado et al., 1984; Nance et al., 1990). BWS instead is highly
heterogeneous and can be caused also by alterations to the imprinted
regions 11p15.5 and 11p15.4 loci, which encompass ICR1, H19,
KCNQ1OT1, and CDKN1C (Shuman et al., 1993). Both BWS and Sotos
syndromes are associated with a predisposition to cancer (Mussa et al.,
2016).
Conversely, NSD2 preferentially performs H3K36me2, and in-
dividuals with Wolf-Hirschhom syndrome (WHS) are aﬀected by severe
growth retardation, ID, microcephaly, severe craniofacial anomalies
and cardiac septal defects (Battaglia et al., 2015).
2.3. H3K27and H2A119 modiﬁcations
The activating histone modiﬁcations described above are counter-
acted by the Polycomb Group of proteins (PcG), mainly through
monoubiquitination of Lys 119 of histone H2A (H2AK119Ub) and tri-
methylation of H3K27 (H3K27me3). These two HPTMs are catalysed by
Polycomb Repressive complex 1 (PRC1) and Polycomb Repressive
complex 2 (PRC2), respectively. H3K27me3 is a paradigmatic example
of inherited modiﬁcation across cell generations. Epigenetic memory
was discovered in D. Melanogaster uncovering a mechanism through
which Polycomb and Trithorax mediate the inheritance of the GRNs
established during embryo development through the antagonistic re-
pression and activation of homeotic genes. The marks regulated by
these two axes allow the maintenance of cell identity through devel-
opment and in the adult, long after the initial stimulus (Hathaway et al.,
2012; Steﬀen and Ringrose, 2014), thus ascribing this regulation to the
strong epigenetic deﬁnition.
2.3.1. PRC1
PRC1 is a heterogenous complex which can have both a canonical
composition and a non-canonical one. The core of PRC1 comprises four
components: RING, CBX, PCGF1 and HPH. There are two catalytical
homologues, RING1 and RING2, although RING2 is more prevalent
(Wang et al., 2004). Moreover, there are three HPH homologues
(HPH1, HPH2, HPH3); ﬁve CBX (CBX2, CBX4, CBX6, CBX7, CBX8); and
six PCGF (PCGF1-6). The CBX proteins are able to bind to the
H3K27me3 deposited by PRC2, thereby enabling the recruitment of
PRC1 on PRC2 targets. The lack of a CBX protein deﬁnes the non-ca-
nonical PRC1, which was instead proved to undergo H3K27me3-in-
dependent recruitment (Gao et al., 2012; Tavares et al., 2012;
Vandamme et al., 2011).
PRC2-associated mutations and eﬀects constitute a good example of
convergence as characterized by the network of eﬀects. Although no
dominant germline mutations have been described for the catalytic
components of PRC1, autosomal recessive mutations of PHC1 (pre-
viously known as HPH1) cause a form of microcephaly with short sta-
ture, reported in two Saudi siblings (Awad et al., 2013). Moreover,
HPH1 depletion was associated with decreased histone H2A ubiquiti-
nation and Geminin overexpression (Awad et al., 2013). Geminin mu-
tations are in turn associated with Meier-Gorlin syndrome, an auto-
somal dominant disorder featuring dwarﬁsm (Burrage et al., 2015).
Another PRC2 component, PCGF4 (also known as BMI1), was shown to
be essential for the development of the cerebellum (Leung et al., 2004).
The network of vulnerability also extends to interactors of PRC1 such as
AUTS2, whose mutations are responsible for an autosomal dominant
form of syndromic mental retardation. Individuals carrying AUTS2
mutations have ID along with microcephaly, ASD, short stature, cere-
bral palsy, and facial dysmorphisms (Beunders et al., 2013; Nagamani
et al., 2013). The PRC1-AUTS2 complex acts as positive gene expression
regulator, especially for genes expressed in the central nervous system,
thus expanding the repertoire of functions for PRC1 beyond repressing
transcription. Within this complex, the component Casein Kinase II
(CK2), a key element of the Wnt signaling (Gao and Wang, 2006), in-
hibits PRC1 activity. Upon binding to chromatin, AUTS2 recruits CBP/
p300,which acetylate histone tails in the target region (Gao et al.,
2014). Moreover, mutations in the gene CSNK2A1, which codes for
CK2, cause the Okur-Chung syndrome, characterized by ID, micro-
cephaly, cortical malformations, and variable facial dysmorphisms
(Okur et al., 2016).
2.3.2. PRC2
PRC2 is composed of the catalytically active and mutually exclusive
EZH1 and EZH2, the two enzymes capable of depositing H3K27me3
(Czermin et al., 2002; Kuzmichev et al., 2002), and the subunits EED
and SUZ12 (Laible et al., 1997; Margueron et al., 2008). The two cat-
alytic components have a diﬀerent distribution, as EZH2 is mainly ex-
pressed in undiﬀerentiated cells and during embryogenesis, while EZH1
is more ubiquitously expressed in adult and quiescent cells. Moreover,
EZH2 has stronger catalytic activity than EZH1 (Margueron et al., 2008;
Shen et al., 2008). Accordingly, the catalytic subunit EZH2 together
with EED and SUZ12 are essential for development, as null mutations
result in embryonic lethality, displaying severe developmental and
proliferative alterations (O'Carroll et al., 2001; Pasini et al., 2004).
The propagation of H3K27me3 through cell divisions is mediated by
the association of the PRC2 complex to the Polycomb-responsive ele-
ments (PREs) in the S-phase, during which it recognizes previously
methylated histones through EED, and modiﬁes the new ones (Hansen
et al., 2008; Margueron et al., 2009). In a way that indicates the most
literal deﬁnition of epigenetics, H3K27me3 has a primary role in the
inheritance of the repressed transcriptional states, as shown in D. mel-
anogaster where the repressed state of HOX genes is maintained even
after the excision of the PREs from the genome (Coleman and Struhl,
2017).
The ﬁne regulation of the PRC2 axis, mediated by the deposition
and removal of H3K27me3, is a key feature in neurodevelopment
(Burgold et al., 2008, 2012; Fragola et al., 2013; Park et al., 2014;
Testa, 2011). The two enzymes that counteract the PRC2 axis are
KDM6A and KDM6B. They are mutated in Kabuki Syndrome (see
above), and in individuals with an autosomal recessive form of mental
retardation (Kuss et al., 2011; Najmabadi et al., 2011) respectively. In
addition, both KDM5B, KDM6A and KDM6B copy variants are asso-
ciated with ASD risk (Sanders et al., 2015). In particular, EZH2 has a
clear role during neurodevelopment, as its knockdown during neuro-
genesis causes alterations in the migration of the maturating neurons,
due to the de-repression of Reelin (Zhao et al., 2015). Moreover, the
knockdown of EZH2 in the neural tube of chicken embryos leads to
defects in the apicobasal polarity of neuroblasts, thus causing impaired
neural tube organization, which is mediated by the cell cycle regulator
p21WAF1/CIP1 (Akizu et al., 2016). This evidence hints to a role of EZH2,
and more broadly of PRC2, in neurodevelopment, but an exhaustive
picture of how its ﬁne regulation occurs throughout human neurogen-
esis still needs to be drawn. More recently, an elegant study using
mouse ESCs proposed a potential mechanism for this global regulation
by showing that poised enhancers establish physical interactions with
their target genes in a PRC2-dependent manner (Cruz-Molina et al.,
2017). Loss of PRC2 in undiﬀerentiated mESCs led to neither the acti-
vation of poised enhancers nor the induction of their putative target
genes in undiﬀerentiated ESCs. Instead, upon mESC diﬀerentiation, the
loss of PRC2 severely and speciﬁcally compromised the induction of
major anterior neural genes, representing poised enhancer targets. The
authors suggest that polycomb proteins facilitate neural induction by
providing major anterior neural loci accessibility through a permissive
regulatory topology, which may constitute a “default” model of neural
induction (Cruz-Molina et al., 2017).
Mutations in EZH2 cause Weaver Syndrome (WVS), an overgrowth
syndrome characterized by ASD and accelerated osseous maturation,
developmental delay and characteristic facies (Gibson et al., 2012;
Weaver et al., 1974).WVS diﬀers from Sotos syndrome (see above) by
the typical facies and for an advanced carpal bone development.
Moreover, individuals with WVS, negative for EZH2mutations, harbour
mutations in the essential subunits SUZ12 and EED (Cohen and Gibson,
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2016; Cooney et al., 2017; Imagawa et al., 2017; Tatton-Brown et al.,
2017). According to the overgrowth and macrocephaly phenotypes
observed in the Weaver syndrome, conditional KO of EZH2 induces an
accelerated proliferation of neuronal precursor in the cerebral cortex,
which results in a premature increase of neuron numbers and diﬀer-
entiation to astrocytes, at the expense of the number of neurons at birth
(Pereira et al., 2010).
2.4. Histone Acetylation
Histone acetylation is regulated by the dynamic balance between
Histone acetyltransferases (HATs), and Histone deacetylases (HDACs)
(Haberland et al., 2009). The negative charge of the acetyl group can
neutralize the lysine positive charge, thus relaxing the nucleosome
structure that becomes more accessible to the transcriptional machinery
(Zhang et al., 2015). Moreover, the acetylated lysines can be “read” by
the bromodomain-containing proteins, that are therefore able to med-
iate the interaction with other chromatin remodelling complexes and
transcription factors (TFs). Lysine acetylation is associated with active
promoters and active enhancers (Lawrence et al., 2016; Pradeepa,
2017) and with transcriptional memory as shown in S. pombe, in which
gene expression can be triggered and maintained by transient exposure
to HDAC inhibitors (Ekwall et al., 1997). Human HATs can be divided
into two major groups based on their sub-cellular localization: i) Type A
HATs, which contain a bromodomain and reside in the nucleus, where
they acetylate nucleosomal histones, and which are further subdivided
in three classes based on their homology, Gcn5/PCAF, MYST and p300/
CBP; ii) Type B HATs, which lack the bromodomain and reside in the
cytoplasm where they acetylate newly synthesized histones (Bannister
and Kouzarides, 2011). In humans, 18 HDACs deacetylate histones and
non-histone proteins and they are divided in four sub-classes (I-IV)
(Seto and Yoshida, 2014).
CBP and p300 associate in the CBP/p300 complex, responsible for
H3K27, H3K56, H3K64 and H3K122 acetylation (Bannister and
Kouzarides, 1996; Das et al., 2009; Di Cerbo et al., 2014; Ogryzko et al.,
1996; Tropberger et al., 2013). Mutations in CREBP and EP300 are
responsible for Rubinstein–Taybi syndrome (RSTS). Mutations in
CREBP explain around 50–70% of RSTS cases. RSTS main features are
ID, microcephaly, growth deﬁciency, dysmorphic facies, and broad
thumbs and halluces. Moreover, RSTS individuals have an increased
risk of developing cancer (Hennekam, 2006; RUBINSTEIN and TAYBI,
1963). Due to the high pleiotropy of CBP/p300, the human molecular
pathogenesis mechanism is not clear. The ﬁrst study on human samples
showed hypoacetylation of H2A and H2Bin lymphoblastoid cell lines,
which could be rescued by HDAC inhibitors (Kazantsev et al., 2008).
A prominent interactor of p300/CBP is YY1 (Lee et al., 1995), a
multifunctional Zinc Finger able to repress or promote gene expression
depending on the interactors present in each cell state, and mediates
long-range DNA interactions (Atchison, 2014). YY1 has a fundamental
role in development since its deletion results in embryonic lethality
(Donohoe et al., 1999). Moreover, YY1 mediates gene activation in-
teracting with the chromatin remodeling complex INO80 (Cai et al.,
2007; Vella et al., 2012; Wu et al., 2007). Recently, YY1 mutations have
been identiﬁed as responsible for Gabriele-DeVries syndrome
(GADVES), a syndromic intellectual disability characterized by growth
retardation, various congenital malformations, and feeding problems
(Gabriele et al., 2017). In human cells, YY1 haploinsuﬃciency leads to
a widespread loss of H3K27Ac, and gain of H3K27me3 selectively in
enhancer regions that were occupied by YY1. These observations sug-
gested GADVES to be an enhanceropathy caused by a defect of long-
range enhancer-promoters interaction mediated by YY1 (Gabriele et al.,
2017). Accordingly, research has recently shown that YY1 directly
regulates enhancer-promoter looping (Weintraub et al., 2017). More-
over, YY1 interacts with CTCF, they co-occupy genomic regions
(Schwalie et al., 2013), and, along similar lines of evidence, an in-
dependent study has showed that YY1, together with CTCF, mediates
interaction between enhancers and promoters of target genes involved
in neuronal diﬀerentiation (Beagan et al., 2017). Consistently with this
role and YY1 interaction with CTCF, mutations in the latter cause in-
tellectual disability with microcephaly, growth retardation and heart
defects (Gregor et al., 2013).
Regarding the MYST family, KANSL1 acts as a scaﬀold in the Non-
Speciﬁc Lethal (NSL) complex, in which MYST1 performs both H4K5,
H4K8, and H4K16 acetylation (Su et al., 2016), and acetylation of non-
histonic proteins such as p53 (Sykes et al., 2006). Moreover, KANSL1
interacts with the COMPASS subunit WDR5 (Dias et al., 2014), and
H4K16Ac promotes H3K4me2 deposition by activating the COMPASS/
KMT2A complex (Zhao et al., 2013). In humans, mutations in KANSL1
cause Koolen-de Vries syndrome (KDVS). The main features of KDVS
are hypotonia, moderate to severe ID, distinctive facies, and a friendly
behaviour (Koolen et al., 2012). Interestingly, a microduplication of the
same region is associated with ASD, a phenotype opposed to the mi-
crodeletion causing KDVS (Grisart et al., 2009).
HDAC8, a Class I deacetylase, whose in vitro substrates are H3 and
H4 (Hu et al., 2000), is responsible for a variant of Cornelia de Lange
syndrome (see above). However, in vivo, HDAC8 is now known to
deacetylate non-histone proteins (Wolfson et al., 2013). In addition, the
phenotype of the KBG syndrome is thought to be mediated by the
ability of ANKRD11 to interact and activate HDAC3 (Gallagher et al.,
2015).
2.5. Histone phosphorylation
Like histone acetylation, histone phosphorylation is highly dynamic.
Hydroxyl- containing aminoacids, such as serine and threonine, can be
phosphorylated and dephosphorylated. The best-characterized phos-
phorylation site on histones is the serine 10 of H3 (H3S10), which is
associated with gene activation (Ivaldi et al., 2007; Zippo et al., 2007).
A complete review of this modiﬁcation and its role in the CNS can be
found elsewhere (Banerjee and Chakravarti, 2011; Maze et al., 2013).
So far, only a few NDDs have been associated to this histone mod-
iﬁcation. Mutations in RPS6KA3, which codes for a H3S10 kinase
(RSK2), cause Coﬃn–Lowry syndrome, a rare X-linked condition asso-
ciated with severe mental retardation, skeletal and cardiac defects,
movement alterations, growth retardation, craniofacial, dental and di-
gital abnormalities, auditory and visual defects (Marques Pereira et al.,
2010). In addition, mutations in the gene for RSK4, another H3S10
kinase, have been associated to an X-linked form of mental retardation,
though the original observation awaits further conﬁrmation (Yntema
et al., 1999).
3. Chromatin remodelling
There are four main families of ATP-dependent chromatin re-
modeling complexes: the SWI/SNF (known as the BAF complex in
human, from Brg/Brm-associated factor), INO80, ISWI and the CHD
family. These families use ATP to move nucleosomes laterally on DNA,
to exchange nucleosomes and to reduce the DNA-nucleosome interac-
tion. Chromatin remodelers target speciﬁc nucleosomes close to pro-
moter regions where they control both gene repression and activation
(de Dieuleveult et al., 2016), and are involved in the inheritance of the
chromatin state and the maintenance of transcriptional memory. As a
pivotal example, experiments in yeast showed that the maintenance of
the expression of GAL genes is mediated by the incorporation of H2A.Z,
mediated by SWI/SNF (Margueron and Reinberg, 2010). Mutations in
the above-mentioned chromatin players highlight their importance in
early development and cell cycle control. In mice, homozygous muta-
tions in SWI/SNF components such as Brg1 or Brm are embryonic lethal
or lead to increased cell proliferation, respectively; ablation in the ISWI
and CHD components results in death before birth (de la Serna et al.,
2006). Chromatin remodelling is also involved in the control of long-
range chromatin interactions, as there is strong evidence for the
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involvement of ISWI components in mediating cage-like structures
crucial for IL-2Rα silencing in T-Cell development (de la Serna et al.,
2006).
Several chromatin remodelling complexes have key roles in the
formation and function of the brain. Among the best-studied ones are
the BAF complexes, which regulate neurite axonal maturation and ar-
borization. Many BAF complex subunits are involved in the nervous
system development in processes such as axonal diﬀerentiation, pyr-
amidal layer-speciﬁc identity acquisition, gliogenesis and oligoden-
drogenesis repression, and in the establishment of learning and memory
(Ronan et al., 2013b; Sokpor et al., 2017). Moreover, during early
phases of development, the SMARCA4 complexes maintain the stem-
ness of neuronal progenitors through the inhibition of genes responsible
for neuronal diﬀerentiation, mediating the interaction of repressor
element 1-silencing transcription factor (REST) with chromatin (Ooi
et al., 2006). In addition, a targeted deletion in the nervous system of
Brg, the ATPase subunit of SWI/SNF, causes defects in neural tube
closure and smaller brains with cerebellum agenesis (Lessard et al.,
2007).
As a notable example of convergence, heterozygous mutations
identiﬁed in several components of the BAF complex (SMARCA2,
SMARCA4, SMARCB1, SMARCE1, ARID1A and ARID1B) lead to distinct
but largely overlapping intellectual disability syndromes referred to
as“SWI/SNF-related ID syndromes” (Kosho et al., 2013; Santen et al.,
2013). The overlap is evident when considering that haploinsuﬃcient
mutations lead to severe intellectual disability and developmental ab-
normalities regardless of the aﬀected subunit, pointing to a critical role
of this complex in early stages of brain development (Vogel-Ciernia
et al., 2013; Vogel-Ciernia and Wood, 2014). Speciﬁcally, mutations of
ARID1A, ARID1B, SMARCA4, SMARCB1 and SMARCE1 cause Coﬃn-
Siris syndrome (CSS) which is a multisystemic disorder characterized
by ID, dysmorphic facies, microcephaly, development delay, congenital
heart defects, sparse scalp hair, hypoplasia of the ﬁfth digit, and spinal
anomalies (Vergano and Deardorﬀ, 2014; Wieczorek et al., 2013).
Moreover, mutations in the TF SOX11, which is regulated by PAX6-
SMARCA4, have been found in a cohort of CSS individuals with a
milder phenotype (Ninkovic et al., 2013; Tsurusaki et al., 2014). SOX11
is expressed exclusively in fetal and adult human brain and adult
human heart (Tsurusaki et al., 2014), thus potentially explaining the
clinical manifestations of these patients.
SMARCA2 mutations cause Nicolaides-Baraitser syndrome (NBS),
which resembles some clinical features of CSS. Individuals aﬀected by
the NBS are characterized by severe ID, microcephaly, seizures, short
stature, sparse scalp hair and dysmorphic facies (Sousa et al., 2009).
NBS can be distinguished from the CSS by the lack of hypoplasia of the
ﬁfth digit and the presence of swelling of the ﬁnger joints, broad
terminal phalanges, short metacarpals and less common internal organ
malformation (Sousa et al., 2009).
ADNP, an interactor of the SWI/SNF complex, is mutated in the
SWI/SNF-related autism syndrome. ADNP C-terminal domain binds the
fundamental components SMARCA4 and SMARCA2, which are the two
core ATPase-subunits, and ARID1A (Mandel and Gozes, 2007). This
syndrome encompasses ASD and mild to severe ID, along with several
other clinical manifestations such as hypotonia, feeding problems,
dysmorphic facies, short stature, hand abnormalities, recurrent infec-
tions and a range of cardiac defects (Helsmoortel et al., 2014;
Vandeweyer et al., 2014). In mice, the depletion of Adnp is embryonic
lethal, and the heterozygous model is aﬀected by cognitive deﬁcits and
neurodegeneration (Vulih-Shultzman et al., 2007).
Mutations in CHD7 are responsible for CHARGE syndrome
(Sanlaville et al., 2005). The acronym “CHARGE” describes the most
recurrent clinical phenotypes: Coloboma, Heart defects, Atresia of the
choanae, Retarded growth and development, Genital hypoplasia, Ear
abnormalities (Källén et al., 1999). CHD7 interacts with active en-
hancers to modulate cell-speciﬁc gene expression (Schnetz et al., 2010).
Given the common embryological origin of aﬀected tissues, CHARGE
syndrome is thought to be caused by abnormalities in Neural Crest Stem
Cells development (NCSC). Accordingly, CHD7 is required for NCSC
diﬀerentiation and its knockdown impairs NCSC migration (Bajpai
et al., 2010). Moreover, using NCSCs diﬀerentiated from CHARGE pa-
tients-derived iPSCs, it has been described both a transcriptional and
migratory phenotype that supports the NCSCs involvement in CHARGE
pathogenesis (Okuno et al., 2017).
Moreover, CHD7 was shown to interacts with three of the COMPASS
complexes core subunits (WDR5, ASH2L, and RbBP5) (Schulz et al.,
2014) which supports a link between histone methylation and chro-
matin remodeling during neurodevelopment. Consequently, although
CHARGE syndrome and KS are two diﬀerent pathologies, their clinical
overlap is mirrored by a molecular link that suggests common down-
stream GRNs. Moreover, DNA-methylation analysis from whole blood
of KS and CHARGE individuals identiﬁed a shared gain of DNA me-
thylation at HOXA5, which can justify a part of the clinical overlap
between the two syndromes (Butcher et al., 2017). This molecular and
clinical overlap suggests a NCSCs alteration also in KS pathogenesis.
More recently CHD8 has been associated with ASD (O'Roak et al.,
2012). After a “genotype ﬁrst” investigation in a cohort of children with
ASD or developmental delay, CHD8 was found mutated in a subset of
children with similar clinical features. Individuals with CHD8 muta-
tions had macrocephaly, ASD, high stature, hypertelorism, prominent
supraorbital ridge, down-slanted palpebral ﬁssures, ID, attention deﬁ-
cits, sleep and gastrointestinal problems (Bernier et al., 2014). Studies
in D. rerio suggest that the neurological features may be related to a
reduction of post-mitotic enteric neurons following CHD8 disruption.
In a human model of neural precursor cells, CHD8 was shown to
regulate pathways associated with ASD (Sugathan et al., 2014). More
recently, two studies described the diﬀerentiation in early cortical
neurons, neural progenitors, and cortical organoids derived from in-
duced Pluripotent Stem Cells engineered to carry CHD8 mutations, to
address the eﬀect of CHD8 homozygosity (Wang et al., 2015, 2017). A
Gene Ontology analysis performed on the sets of diﬀerentially ex-
pressed genes revealed a signiﬁcant enrichment in categories related to
neurodevelopment. In particular, the authors identiﬁed some recur-
rently upregulated genes, relevant for neurodevelopment, such as the
non-coding RNA DLX6-AS1, DLX1, and TCF4. Notably, DLX6-AS1 reg-
ulates GABAergic interneurons development (Berghoﬀ et al., 2013).
The transcription factor DLX1, together with its homologous DLX2, had
already been associated with ASD (Liu et al., 2009). Also, TCF4 is a TF
already known for a corneal dystrophy and the Pitt-Hopkins syndrome,
another severe NDD (Zweier et al., 2007).
Microcephaly is a feature of both CSS and NBS. This phenotype is
thought to be caused by a premature depletion of the neuronal pre-
cursor, as a consequence of the deletion of the BAF subunits. As op-
posed to the PRC2 axis and the role of CDH8, BAF complexes are ne-
gative regulators of the Wnt/β-catenin pathway. This molecular
asymmetry is also present at the clinical level: Weaver syndrome in-
dividuals and CDH8mutation carriers have macrocephaly (Ronan et al.,
2013b), which is also a hallmark feature of Okur-Chung syndrome,
caused by mutations in CK2 (see above). Thus, the direction of cephalic
abnormalities seems to be tightly linked to the direction of the de-
rangements in the regulation of the Wnt/β-catenin pathway, under-
scoring how the ﬁne regulation of transcriptional programs orche-
strated at diﬀerent layers of epigenetic regulation, such as chromatin
architecture and histone modiﬁcations, is crucial for proper develop-
ment.
Recently, YY1AP1, a component of the INO80 complex and inter-
actor of YY1, was reported as the cause of Grange syndrome and a ﬁ-
bromuscular dysplasia-Like vascular disease that encompasses arterial
and heart defects, bone fragility, brachydactyly, learning disabilities,
and borderline ID (Guo et al., 2017).
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4. DNA methylation
DNA methylation (DNAm) was the ﬁrst epigenetic modiﬁcation
identiﬁed (HOTCHKISS, 1948) and constitutes the best example of
hereditable epigenetic mark. The methylation of cytosine to 5-methyl-
Cytosine (5mC) is propagated to daughter cells thanks to the semi-
conservative DNA replication, and fully restored by the maintenance
enzyme DNMT1 which preferentially methylates hemimethylated sites
(Hermann et al., 2004). De novo methylation is performed DNA me-
thyltransferases DNMT3A and DNMT3B (Bestor, 2000; Okano et al.,
1999). Several lines of evidence underscore the fundamental role of
these enzymes: Dnmt1 depletion in mice leads to embryonic lethality;
Dnmt3a and Dnmt3b depleted mice die several weeks after birth and in
utero, respectively (Margueron and Reinberg, 2010; Okano et al.,
1999). Classically, 5mC was thought to be deposited only at CpG nu-
cleotides. However, the existence of non-CpG DNAm, which becomes
the prevalent methylation mark in the mature nervous system (Guo
et al., 2013; Lister et al., 2009, 2013), is now well established. The
removal of 5mC is mediated by a sequential oxidation process per-
formed by a class of dioxygenases collectively named TET (ten-eleven
translocation) (Tahiliani et al., 2009), which oxidate 5mC to 5-hydro-
ximethylcytosine (5hmC), to 5-formilcytosine (5fC), and 5-carbox-
ylcytosine (5caC). The restoration of an unmodiﬁed cytosine is per-
formed by the Base Excision Repair (BER) mechanism in the presence of
5fC or 5caC (He et al., 2011; Maiti and Drohat, 2011). The recognition
of methylated DNA is independent of the sequence and is mediated by
methyl-(mCpG)-binding domain (MBD) proteins (Zhang et al., 1999).
The ﬁrst discovered MBD protein is MeCP2 (Meehan et al., 1989), also
able to bind 5hmC, which is enriched in active genes (Guo et al., 2013;
Mellén et al., 2012). Nevertheless, also TFs lacking an MBD are able to
interact with methylated-DNA (Bartke et al., 2010; Spruijt et al., 2013).
In the classical view, CpGs in the genome are globally methylated and
DNAm is associated with transcriptional repression and gene silencing
(Razin and Riggs, 1980). Accordingly, un-methylated CpG islands are
associated with promoter regions of active genes (Bird et al., 1985;
Deaton and Bird, 2011). In addition to the repressive role, DNAm has a
key role in enhancer activation (Charlet et al., 2016) mediated by the
formation of 5hmC at enhancer sites following the action of DNMT3A
and DNMT3B (Rinaldi et al., 2016). Additionally, gene body methyla-
tion performed by DNMT3B induces gene expression (Yang et al.,
2014).
Mutations in virtually all the components of the DNA-methylation
machinery result in NDDs. Mutations in DNMT1 are responsible for a
hereditary neuropathy characterized by progressive peripheral sensory
loss, progressive hearing impairment and early-onset dementias as well
as with a neurological disorder associated with cerebellar ataxia,
deafness, and narcolepsy (Klein et al., 2011). In contrast to many syn-
dromes described until now, these two are neurodegenerative disorders
with adult onset. Mutations in DNMT3A give rise to the Tatton-Brown-
Rahman syndrome, an overgrowth syndrome associated with a dis-
tinctive facies and ID (Tatton-Brown et al., 2014). Finally, mutations in
DNMT3B cause a recessive “immunodeﬁciency-centromeric instability
facial anomalies” syndrome (Bestor et al., 1999). A recent study which
employed human embryonic stem cells (Liao et al., 2015), to study the
role of the DNA methylases, described that the deletion of DNMT1
causes rapid cell death; while in a conditional model it causes a massive
loss of DNA methylation. The separate or combined deletion of
DNMT3A and DNMT3B induces viable cells capable of diﬀerentiating in
the three germ layers, but with diﬀerent patterns in DNAm alterations,
including a milder impact following the deletion of only one of the two
genes. Consequently, these results suggest that DNMT3A and DNMT3B
have both shared and unique targets. The presence of speciﬁc targets
might explain the fact that only mutations DNMT3B have a recessive
inheritance (Liao et al., 2015).
Mutations in MeCP2 are the main cause of Rett syndrome (RTT),
(Zoghbi et al., 1999), with mutations in FOXG1 accounting for a minor
fraction of the cases (Van der Aa et al., 2011). Since MeCP2 is located on
the X chromosome, its loss-of-function mutations give rise to distinct
phenotypes in males and females. Males are aﬀected by a severe form of
encephalopathy with early lethality within usually 1 year of age. Fe-
males instead, owing to the expression of the normal allele in about half
of the cells, are spared from encephalopathy but go on to develop the
deﬁning hallmarks of Rett syndrome (Zoghbi, 2016), which has become
one of the best studied NDDs, due to its high prevalence and severe
phenotype. In RTT, initial development is normal but it is arrested
between 6 and 18 months of age. The onset is characterized by re-
gression of intellectual and motor capabilities. Indeed, loss of speech,
regression of motor skills, hands stereotypic movements, ID, seizures,
and delayed head growth resulting in microcephaly are all observed in
these patients. A post-mortem study showed that RTT brains have a
consistently decreased expression of presynaptic markers, and an in-
creased expression of glial markers involved in neuropathologies
(Colantuoni et al., 2001). Several human iPSC-based models have been
established, and the ﬁrst human neuronal characterization of an RTT
iPSC-based model unveiled a reduction in synapses, dendritic spines,
and neuron body size (Marchetto et al., 2010). Many other studies
corroborated these results (Ananiev et al., 2011; Cheung et al., 2011;
Kim et al., 2011). Additionally, MeCP2 mutated individuals have a
higher susceptibility to L1 retrotransposition (Muotri et al., 2010). The
analysis of gene expression in neural precursors and mature neurons
obtained by the diﬀerentiation of iPSCs derived from individuals with
mutations in MeCP2 or CDKL5, whose mutations cause an epileptic
encephalopathy with phenotypic overlap with RTT (Guerrini and
Parrini, 2012), showed a downregulation of glutamate receptor subunit
GRID1 in iPSCs and upregulation in neuronal precursor for both back-
grounds when compared to an healthy control (Livide et al., 2015).
GRID1 codes for GluD1, which is necessary for synapse development
but dispensable for channel function (Mayat et al., 1995; Yasumura
et al., 2012). Further experiments in neurons diﬀerentiated from iPSCs
of FOXG1-mutated individuals showed that GluD1 alteration leads to an
unbalanced increase in inhibitory synapsis (Patriarchi et al., 2016). In
addition, neurons derived from iPSCs of CDKL5 mutated individuals
showed that CDKL5 localizes at excitatory synapses, where contributes
to dendritic spine development and synapses activity. In particular,
VGLUT1 and PSD95 puncta were signiﬁcantly reduced in mutants
(Ricciardi et al., 2012).
DNAm is also responsible for the process of the imprinting, a genetic
mechanism that ensures the expression of some genes only from the
maternal or paternal allele. The molecular mechanisms of imprinting
and the diseases caused by a defect of DNAm or the deletion of the
expressed allele are extensively reviewed elsewhere (Buiting et al.,
2016; Elhamamsy, 2017; Mackay and Temple, 2017).
5. Multiple genes dosage imbalance
Except for few diseases with a recessive inheritance, most NDDs
addressed until now are dominant and caused by deletion, frameshift,
missense or nonsense mutations of one allele. Therefore, genes involved
in these haploinsuﬃciency syndromes have a pivotal role and the bal-
ance of their stoichiometry is essential to maintain the equilibrium in
their GRNs. Sometimes, deletions or duplications can aﬀect entire
chromosomes, such as in aneuploidy syndromes (Hutaﬀ-Lee et al.,
2013), or encompass large chromosomal regions with multiple genes.
The understanding of the molecular cause of these syndromes is more
complex since the phenotype is the result of the gain or loss of several
genes, and each of the genes involved can be responsible for a speciﬁc
portion of the clinical manifestation. Well known examples of gene
dosage imbalance caused by the complete gain or loss of a chromosome
are the Down, the Klinefelter, and the Turner syndrome. Given the
complexity of these syndromes, we refer the reader to specialised re-
views (Antonarakis, 2016; Bonomi et al., 2017; Morris, 2017).
In contrast, microduplication and microdeletion syndromes
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involving far fewer genes, make it possible to dissect their speciﬁc
contribution to a given pathogenesis. Two well-known examples of
microdeletion and microduplication syndromes which appear to have a
dosage-dependent phenotype are Williams Beuren Syndrome (WBS),
caused by the deletion of the region 7q11.23, which contains 28 genes,
(BEUREN et al., 1962; WILLIAMS et al., 1961), and its counterpart,
7q11.23 duplication syndrome (7dup) (Van der Aa et al., 2009). Both
syndromes display opposite and shared clinical manifestations. Among
the shared ones are ID, craniofacial dysmorphisms, heart defects, me-
tabolic alterations and genitourinary anomalies. Conversely, the
opposite phenotypes include WBS hyper-sociability behaviour in WBS,
while 7dup individuals are usually aﬀected by ASD, which indicates the
existence genes in the region that participate in pathways regulating
aspects of neurodevelopment that later inﬂuence social behaviour.
To understand the role of each of the 28 genes in the pathogenesis of
the two syndromes, some studies have used phenotypes in patients with
atypical deletions, which spare some of the interval's genes, causing
milder and/or more selective clinical manifestations. Notably, in-
dividuals with an atypical 7q11.23 deletion that spares GTF2I retain
their neuro-cognitive abilities (Antonell et al., 2010; Dai et al., 2009;
Fig. 2. Transcription regulation is controlled by DNA methylation, nucleosome remodeling, and histone modiﬁcations. The deposition of histone markers, performed by histone me-
thyltransferases (HMTs) and histone acetyltransferases (HATs), is counterbalanced by the removal achieved by histone demethylases (HDMs) and histone deacetylases (HDACs).
Nucleosome positioning and DNA accessibility are regulated by ATP-dependent chromatin remodeling complexes. Cytosines are modiﬁed with methyl groups by DNA methyltransferases.
The balance between activating and repressive markers and nucleosome positioning is responsible for the ﬁne tuning of time and space speciﬁc gene expression. The alteration of such
regulation during individual development leads to various Neurodevelopmental Disorders (NDDs) highlighting the vulnerability of gene regulatory networks (GRNs).
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Edelmann et al., 2007; Ferrero et al., 2010). GTF2I codes for the Gen-
eral Transcription Factor II-I, a component of histone deacetylase-con-
taining complexes which contain HDAC1, HDAC2 and KDM1A (ori-
ginally calledBHC110) (Hakimi et al., 2003). Further underscoring the
importance of GTF2I, independent studies described single nucleotide
polymorphisms (SNPs) in GTF2I associated with ASD, social anxiety,
reduced social communication skills and amygdala activation by aver-
sive stimuli (Crespi and Hurd, 2014; Malenfant et al., 2012; Swartz
et al., 2017). The ﬁrst WBS and 7dup disease modelling study demon-
strated that about 30% of diﬀerentially expressed genes observed in
iPSCS across both syndromes are linked to GTF2I regulation (Adamo
et al., 2015). Additionally, this study showed that GTF2I is associated
substoichiometrically with KDM1A and HDAC2, implying a dual role in
both directly and indirectly in transcriptional regulation. In keeping
with the copy number variation of regulators of gene expression, the
transcriptional dysregulation observed at the pluripotent stage was
propagated and ampliﬁed in the neuronal precursor, neural crest stem
cells, and mesenchymal stem cells (Adamo et al., 2015). Another
human model study corroborates the transcriptional ﬁndings of Adamo
et al. and focuses on FZD9, a receptor of the Wnt pathway in the
7q11.23 region, showing that it is essential to prevent cell death in
neuronal precursors (Chailangkarn et al., 2016). Additionally, the au-
thors diﬀerentiated iPSCs in cortical neurons, with a particular em-
phasis for cells expressing cortical markers for layers V/VI, given their
involvement in ASD (Hutsler and Zhang, 2010). Following diﬀerentia-
tion, data showed an increase in dendritic length and spine number, in
accordance with observation made from WBS post-mortem brains in-
dividuals, suggesting that this phenotype may generate the altered
network activity implicated in the neurocognitive features
(Chailangkarn et al., 2016). In another study, blood cells of WBS, 7dup
and healthy individuals were proﬁled for their DNAm content, which
reﬂected gene dosage (Strong et al., 2015). Another example of chro-
matin regulator contained in the 7q11.23 region is BAZ1B, a bromo-
domain protein which interacts with SMARCA5 (Bozhenok et al.,
2002). BAZ1B haploinsuﬃciency was found to contribute to WBS
through transcriptional dysregulation of neurodevelopmental pathways
(Lalli et al., 2016).
6. Conclusions
Our aim has been to provide a temporal and developmental framing
for the rapidly accumulating knowledge on the derangement of epige-
netic regulation that underlies neuropsychiatric disorders. A clariﬁca-
tion of the epistemic reach of epigenetics has been integral to this ap-
proach, ushering in a review of the ﬁeld that clearly distinguishes,
within the expanding list of chromatin pathways causally linked to
NDD, those mediating bona ﬁde epigenetic inheritance of cell states
from those aﬀecting gene expression more dynamically (and whose
pathogenic mechanism is thus not necessarily linked to strictly deﬁned
epigenetic alterations). The comprehensive extent of this classiﬁcation
is summarized in Fig. 2 and Table 1 with the list of NDDs caused, re-
spectively, by mutations in epigenetic regulators and related tran-
scription factors. Importantly, we have brought to the fore, whenever
possible, both the numerous NDDs that are already related at the mo-
lecular mechanistic level and those in which a clear molecular link is
still lacking but that display nonetheless signiﬁcant phenotypic con-
vergence, hinting at convergent downstream pathways. One example of
similar phenotypes caused by molecular convergence is the common
occurrence of overgrowth in multiple NDDs caused by mutations in
repressive chromatin modiﬁers, such as in DNMT3A, EED, EZH2, CHD8,
NSD1, and SETD2. On the other hand, mutations in molecular pathways
associated with gene activation such as SMARCA2, SMARCA4, missense
mutations in KMT2A, KMT2B, KMT2D, EHMT1, are often causative of
microcephaly. One common convergent mechanism responsible for this
phenotype is the Wnt/β-catenin pathway, which plays a pivotal role in
the balance of progenitor proliferation in the developing cortex and
whose impairment leads to macrocephaly or microcephaly. However,
there are other cases of microcephaly and macrocephaly with no clear
link to wnt/β-catenin pathway, such as for NSD2 or CTCF, highlighting
the pleiotropy of the phenotypes.
In order to provide a visual summary of what is discussed here, we
have portrayed a spatial mapping of the distribution of the expression
of epigenetic modiﬁers across the adult brain according to the GTEx
dataset (Carithers et al., 2015; GTEx Consortium, Laboratory, et al.,
2017). This highlights the cortex as the area with the highest levels,
with particular emphasis in the Brodmann area 9 (BA9), which is in-
volved in various higher cognitive functions often disrupted in multiple
NDDs and ASD, including empathy and processing of pleasant and
unpleasant emotions(Carlén, 2017; Lane et al., 1997) (Fig 3A, B).
Likewise, an analysis of their relative expression throughout develop-
ment and adulthood within the BrainSpan atlas RNA-seq dataset (Oldre
et al., 2014), highlights the fact that most of the genes commonly
mutated in NDDs display an expression pattern increased in the gesta-
tional period, which agrees with the concept of early development as a
particularly susceptible window in which mutations in these genes re-
sult in their highest phenotypical impact.
It is plausible to think that the function of these genes is highly
required at the beginning of the development, during diﬀerentiation
and the acquisition of cell identity, when dramatic changes in chro-
matin structure happen to prime the expression of diﬀerentiation and
function-speciﬁc genes. Consequently, mutations in these genes have
their most substantial impact during the most fragile developmental
phase. Nevertheless, the same genes are still required also in adult
neuronal tissues, since it is well known that histone modiﬁcations and
DNAm are involved in processes as neuronal plasticity, learning and
memory acquisition (Kaang and Kim, 2017). In Fig. 3C we also high-
light the expression proﬁle in the cortex and the amygdala, a site that
has been considered important in Williams-Beuren syndrome and other
ASDs (Binelli et al., 2016) given its involvement in the regulation of the
emotional response.
Further supporting a common downstream pathway, multiple NDDs
caused by mutations in epigenetic regulators have a recurrent presence
of clinical features such as craniofacial dysmorphisms, immunological
defects, heart abnormalities, and other Neural Crest-derived organs
malformations, indicating that neural crest cells, along with the CNS-
originating neurectoderm from which they emerge, deﬁne a cell lineage
hub highly vulnerable to chromatin perturbation during development.
Consequently, tissues and organs derived from neural crest are often
aﬀected in these categories of NDDs.
Although somatic mutations in many of the genes responsible for
NDDs are also linked to cancer (Crawley et al., 2016), only a small
portion of the NDDs are associated with cancer predisposition (Cross,
2010; Rao and Dou, 2015; TATTON-BROWN and RAHMAN, 2013).
Since also cancer is being increasingly understood as an inherently
developmental disorder, in which the diﬀerentiated cell identity is re-
programmed back to an earlier or at any rate altered developmental
stage (Flavahan et al., 2017), the apparent misalignment between NDD
and cancers caused by – often equivalent - mutations in the same
pathways raises an interesting hypothesis. The NDD-causing mutations,
by operating from the onset of development, might trigger downstream
(and possibly compensatory) mechanisms that would make somatic
cells resistant to the oncogenic side of their impact, which would in-
stead unfold in normally developed cells
The phenotypical convergence between multiple NDDs of varied
molecular origin underscores the importance of identifying shared
GRNs, whose further functional dissection could aﬀord much greater
resolution in genotype-phenotype relationships and deﬁne the core
hubs on which to develop new therapeutic inroads.
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Table 1
Genes involved in chromatin remodeling and transcription regulation causative for Neurodevelopmental disorders. The OMIM column represents the associated phenotype, or gene when
followed by *.
Gene Function Associated syndrome OMIM
ADNP Transcription factor and chromatin remodelling Helmsmoortel-van der Aa syndrome, ADNPassociated autism spectrum disorder 615873
ARID1A Chromatin remodeling Coﬃn-Siris syndrome 614607
ARID1B Chromatin remodeling Coﬃn-Siris syndrome 135900
ARX Transcription factor Mental retardation with or without seizures 300419
ATRX Chromatin remodeling α-Thalassemia mental retardation syndrome X-linked and mental retardation-
hypotonic facies syndrome
301040, 309580
AUTS2 PRC1-AUTS2 activates transcription Association with Mental Retardation 615834
BAZ1B Chromatin remodeler involved in transcriptional regulation,
DNA damage response, DNA replication
Williams-Beuren syndrome,
7q11.23 duplication syndrome
605681*
BCOR Transcriptional repressor Syndromic microphthalmia 2 300166
BRD1 Transcription factor Schizophrenia/bipolar 604589*
BRD2 Transcription factor Autism spectrum disorder 601540*
BRD3 Transcription factor Mental retardation 601541*
BRWD3 Transcription factor Autism spectrum disorder 300659
CDKL5 Serine-threonin kinase Infantile Epileptic encephalopathy 300672
CECR2 Chromatin remodeling Anencephaly 607576*
CHD2 Chromatin remodeling Epileptic encephalopathy, childhood-onset 615369
CHD7 Chromatin remodeling CHARGE syndrome 214800
CHD8 Chromatin remodeling Autism spectrum disorder, CHARGE syndrome 615032
CREBBP HAT Rubinstein–Taybi syndrome 180849
CTCF Chromatin remodelling Mental retardation 615502
DNMT1 DNMT Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant and
Neuropathy, hereditary sensory, type IE
604121, 614116
DNMT3A DNMT Tatton-Brown-Rahman syndrome 615879
DNMT3B DNMT Immunodeﬁciency-Centromeric Instability-Facial Anomalies syndrome 242860
EBF3 Transcription factor Hypotonia, ataxia, and delayed development syndrome 617330
EED PRC2 complex Cohen-Gibson syndrome 617561
EHMT1 HMT of H3K9 Kleefstra Syndrome 610253
EP300 HAT Rubinstein-Taybi syndrome 613684
EZH2 HMT of H3K27 Weaver Syndrome 277590
GCN5L2 HAT Neural tube defects 602301*
GTF2I Transcription factor Williams-Beuren syndrome, 7q11.23 duplication syndrome 194050
GTF2IRD1 Transcription factor Williams-Beuren syndrome, 7q11.23 duplication syndrome 194050
HDAC8 HDAC Cornelia de Lange syndrome 300882
HPH1 PRC1 Complex microcephaly and short stature 615414
JARID1C HDM Syndromic Mental retardation, Claes-Jensen type 300534
KANSL1 Scaﬀold of NSL complex, HAT of H4K5 and H4K16 Koolen-de Vries syndrome 610443
KDM5C HDM of H3K4 Mental retardation 300534
KDM6A HDM of H3K27 Kabuki syndrome 300867
KMT2A HMT of H3K4 Wiedemann-Steiner syndrome 605130
KMT2C HMT of H3K4 Kleefstra Spectrum Syndrome, Autistic Spectrum Disorders 606833*
KMT2D HMT of H3K4 Kabuki syndrome 147920
KMT2F HMT of H3K4 Linked to Schizophrenia 611052*
MBD5 Methyl DNA binding protein 2q23.1 microdeletion mental retardation syndrome 156200
MECP2 Methyl DNA binding protein Rett syndrome 312750
MED12 Bridging of transcription
factors/cofactors and RNA polymerase transcriptiona
regulator
Lujan–Fryns syndrome, Opitz–Kaveggia syndrome 309520, 305450
NBEA kinase anchoring protein Autism spectrum dysorder 604889*
NSD1 HMT of H3K36 and H4K20 Sotos syndrome 117550
NSD2 HMT of H3K4 and H3K36 Wolf–Hirschhom syndrome 194190
PHF21A Component of histone Deacetylase Potocki-Shaﬀer syndrome 601224
PHF6 Transcription factor Borjeson–Forssman–Lehmann syndrome 301900
PHF8 HDM, Transcription factor Mental retardation syndrome Siderius type 300263
POLR1C Core components of the transcriptional
machinery
Treacher-Collins Syndrome, Leukodystrophy, hypomyelinating 248390, 616494
POLR1D Core components of the transcriptional
machinery
Treacher-Collins Syndrome 613717
RNASEH2C Ribonuclease H subunit Aicardi-Goutieres syndrome 610329
RPS6KA3 Serine-threonin kinase Coﬃn–Lowry syndrome 303600
RPS6KA6 Serine-threonin kinase X-linked mental retardation 300303*
SATB2 Chromatin remodelling Glass syndrome 612313
SETD2 HMT of H3K36 Luscan-Lumish syndrome, Sotos-like syndrome 616831
SMARCA2 Chromatin remodeling Nicolaides-Baraitser syndrome 601358
SMARCA4 Chromatin remodeling Coﬃn-Siris syndrome 614609
SMARCB1 Chromatin remodeling Coﬃn-Siris syndrome 614608
SMARCE1 Chromatin remodeling Coﬃn-Siris syndrome 616938
SOX11 Transcription factor Mental retardation 615866
SOX3 Transcription factor Mental retardation with isolated growth hormone deﬁciency 300123
TAF1 Transcription initiation factor X-linked Dystonia-parkinsonism, Mental retardation 314250, 300966
YY1 Transcription factor Gabriele-de Vries syndrome 617557
ZBTB20 Transcriptional repressor Primrose syndrome 259050
ZNF41 Transcription factor Mental retardation 314995*
(continued on next page)
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